Gene: GSK3B (Glycogen Synthase Kinase 3 Beta)
Protein: GSK3β, a serine/threonine-protein kinase
Location: Chromosome 3q13.33
Aliases: GSK-3β, GSK3 beta, Tau tubulin kinase (TTBK)
GSK3β (Glycogen Synthase Kinase 3 Beta) is a multifunctional serine/threonine kinase encoded by the GSK3B gene that plays central roles in numerous cellular processes including glycogen metabolism, gene expression, cell cycle regulation, apoptosis, and neuronal function[1]. In the context of neurodegenerative diseases, GSK3β has emerged as a critical player in Alzheimer's disease pathogenesis through its involvement in tau hyperphosphorylation, amyloid-beta production, synaptic dysfunction, and neuroinflammation. The enzyme represents a major therapeutic target, with numerous inhibitors under development for AD and related disorders.
The human GSK3B gene spans approximately 46 kb and contains 12 exons. The protein isoform (GSK3β) is 420 amino acids in length with a molecular weight of approximately 47 kDa. Alternative splicing produces the closely related isoform GSK3α (51 kDa, 483 amino acids) with distinct but overlapping functions. GSK3β is ubiquitously expressed with high levels in the brain, particularly in neurons of the hippocampus, cerebral cortex, and basal ganglia.
GSK3β possesses a characteristic bilobal kinase domain with the catalytic site located between the N-terminal and C-terminal lobes[1:1]. The enzyme requires priming phosphate groups on substrates at position +4 relative to the target serine/threonine, conferring substrate specificity. Multiple serine/threonine phosphorylation sites regulate GSK3β activity. Tyr216 (in the activation loop) is essential for full activity, while Ser9 provides autoinhibitory regulation.
GSK3β activity is tightly regulated through multiple mechanisms:
Phosphorylation:
Protein Interactions:
Cellular Localization:
GSK3β is one of the principal tau kinases responsible for pathological hyperphosphorylation in AD brains[2]. The enzyme phosphorylates tau at multiple sites implicated in NFT formation:
| Site | Position | Effect |
|---|---|---|
| Ser202 | +1 | Early |
| Thr205 | +3 | Early |
| Ser396 | +4 | Late |
| Ser404 | +6 | Late |
| Thr231 | +5 | Early |
GSK3β collaborates with other kinases (CDK5, MARK, PKA) in tau pathology progression. Elevated GSK3β activity in AD brain correlates with neurofibrillary tangle density, and active GSK3β colocalizes with pretangle neurons, suggesting a causal role.
GSK3β influences amyloid precursor protein (APP) processing and Aβ generation[3]:
The enzyme also mediates toxic effects of Aβ on neurons, creating a vicious cycle of pathology propagation. Aβ oligomers stimulate GSK3β activity through multiple mechanisms.
GSK3β directly modulates synaptic plasticity through phosphorylation of various substrates[4]:
Cognitive deficits in AD correlate with GSK3β-mediated synapse loss. Overactive GSK3β impairs long-term potentiation (LTP) while enhancing long-term depression (LTD), contributing to memory impairment.
GSK3β plays a complex role in neuroinflammation[5]:
However, GSK3β also exerts anti-inflammatory effects in certain contexts, complicating therapeutic targeting.
GSK3β is a central component of the β-catenin destruction complex[6]:
Wnt Signaling → Dishevelled → Inhibits GSK3β → β-catenin accumulation → Gene transcription
In the absence of Wnt signaling, GSK3β (in complex with Axin, APC, and β-catenin) phosphorylates β-catenin, targeting it for ubiquitin-proteasomal degradation. Wnt activation inhibits this complex, allowing β-catenin nuclear translocation and transcription of target genes including those involved in neuroprotection.
The PI3K/Akt pathway provides major negative regulation of GSK3β:
GSK3β is a key mediator of insulin signaling disturbances in AD (Type 3 Diabetes hypothesis):
Multiple GSK3β inhibitors have been developed and tested in AD models[7]:
| Inhibitor | Type | Development Stage | Notes |
|---|---|---|---|
| Lithium | Direct | Approved (mood) | First GSK3 inhibitor |
| Tideglusib | Direct | Phase 2 | Selective, CNS-penetrant |
| AZD1080 | Direct | Preclinical | Highly selective |
| CHIR99021 | Direct | Research tool | Standard.selective |
| VP0.01 | Direct | Phase 1 | Novel formulation |
Lithium:
Tideglusib:
Therapeutic targeting of GSK3β faces significant challenges:
Woodgett JR, Molecular cloning and expression of glycogen synthase kinase-3/factor A (1990). 1990. ↩︎ ↩︎
Avila J, et al. Role of tau phosphory GSK3 in Alzheimer's disease (2010). 2010. ↩︎
Phiel CJ, et al. GSK3alpha produces beta-amyloid (2003). 2003. ↩︎
Peineau N, et al. LTP and GSK3 beta (2007). 2007. ↩︎
Huang WC, et al. GSK3 and neuroinflammation (2019). 2019. ↩︎
Dajani R, et al. [ Crystal structure of GSK3 beta (2001)](https://doi.org/10.1016/S1097-2765(01). 2001. ↩︎